Shalby returns to profit in Q4 FY26, publishes results
Shalby Limited returned to profitability in Q4 FY26 with a consolidated net profit of ₹184.54 million, compared to a loss of ₹19.2 million in the previous year. Revenue from operations increased to ₹2,875.45 million, with EBITDA margins improving to 10.20%. The full-year revenue reached ₹11,414.29 million, supported by strong performance in the MedTech segment. The Statutory Auditors issued an unmodified opinion on the results.

*this image is generated using AI for illustrative purposes only.
Shalby Limited returned to profitability in the fourth quarter of FY26, reporting a consolidated net profit of ₹184.54 million against a loss of ₹19.2 million in the corresponding period of the previous year. The company's revenue from operations rose to ₹2,875.45 million year-on-year, driven by growth across its hospital and MedTech verticals. Operational efficiency improved notably, with EBITDA growing to ₹293 million from ₹209 million in Q4 FY25, and the EBITDA margin expanding to 10.20% from 7.89%. For the full year FY26, consolidated revenue grew to ₹11,414.29 million, while net profit stood at ₹346.87 million.
Consolidated Performance Highlights
The financial turnaround was supported by robust performance in the standalone business and the implant manufacturing segment. The adoption of the new tax regime during the period influenced the profitability metrics. The table below summarises the key consolidated financial metrics for the quarter:
| Metric | Q4 FY25 | Q4 FY26 |
|---|---|---|
| Revenue | ₹2.6 billion | ₹2.9 billion |
| EBITDA | ₹209 million | ₹293 million |
| EBITDA Margin | 7.89% | 10.20% |
| Net Profit / (Loss) | ₹(19.2) million | ₹184.54 million |
Segment and Operational Performance
Shalby Hospitals, Pharma & Franchise contributed 79.16% to the consolidated revenue at ₹2,339.5 million, while Shalby MedTech recorded a 45% year-on-year jump in revenue to ₹400.4 million. The standalone entity reported a 7.6% increase in quarterly revenue to ₹2,142 million, with a net profit of ₹257 million. On the operational front, the hospital business saw a rise in surgery counts, with Arthroplasty procedures growing by 15.4% year-on-year to over 2,650 surgeries in Q4 FY26.
Statutory Auditor's Report
M/s. T R Chadha & Co LLP, Chartered Accountants, issued an unmodified opinion on the standalone and consolidated financial results. The report confirmed that the statements give a true and fair view of the financial position and performance of the company in conformity with applicable accounting standards.
Regulatory Disclosure
Pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company submitted the copies of the advertisement published on May 29, 2026, in the Financial Express for the audited financial results. The results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 27, 2026.
Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE597J01018/87fc75cc798c4a27.pdf
Historical Stock Returns for Shalby
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.04% | +1.24% | +1.34% | -19.53% | -15.64% | +0.96% |
Can Shalby sustain the 45% revenue growth in its MedTech segment in the coming fiscal year?
What strategies are in place to further expand EBITDA margins beyond the current 10.20%?
Will the increase in Arthroplasty procedures drive similar growth in other surgical verticals?


































